Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer.

Fogh SE, Kubicek GJ, Champ C, Intenzo C, Axelrod R, Keane WM, Machtay MM.

Am J Clin Oncol. 2012 Aug;35(4):311-5. doi: 10.1097/COC.0b013e3181ec5f2e.

PMID:
22772424
2.

High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell carcinoma of the upper aerodigestive tract.

Perlow A, Bui C, Shreve P, Sundgren PC, Teknos TN, Mukherji SK.

J Comput Assist Tomogr. 2004 Sep-Oct;28(5):704-9.

PMID:
15480048
3.
4.

Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.

Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA.

Laryngoscope. 2008 Apr;118(4):671-5. doi: 10.1097/MLG.0b013e3181625737.

PMID:
18197136
5.

FDG-PET staging and importance of lymph node SUV in head and neck cancer.

Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, Dusing RW, Machtay M.

Head Neck Oncol. 2010 Jul 16;2:19. doi: 10.1186/1758-3284-2-19.

6.

Positron-emission tomography for surveillance of head and neck cancer.

Ryan WR, Fee WE Jr, Le QT, Pinto HA.

Laryngoscope. 2005 Apr;115(4):645-50.

PMID:
15805874
7.

Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.

Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, Chalian AA, Alavi A, Rosenthal DI.

Laryngoscope. 1999 Jun;109(6):970-5.

PMID:
10369292
8.

Uses and limitations of FDG positron emission tomography in patients with head and neck cancer.

Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ.

Laryngoscope. 1999 Jun;109(6):880-5.

PMID:
10369275
9.

Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.

Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, Schuller DE.

Laryngoscope. 2007 Jul;117(7):1173-9.

PMID:
17603315
10.

Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.

Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, Smith RP, Heron DE, Ferris RL, Johnson JT, Branstetter BF 4th.

Laryngoscope. 2007 Dec;117(12):2129-34.

PMID:
17921898
11.

Positron emission tomography in the evaluation of stage III and IV head and neck cancer.

Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS.

Head Neck. 2001 Dec;23(12):1056-60.

12.

Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer.

Wax MK, Myers LL, Gabalski EC, Husain S, Gona JM, Nabi H.

Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):703-7.

PMID:
12049568
13.

Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.

Fischbein NJ, AAssar OS, Caputo GR, Kaplan MJ, Singer MI, Price DC, Dillon WP, Hawkins RA.

AJNR Am J Neuroradiol. 1998 Aug;19(7):1189-96.

14.

False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.

Gómez-Caro A, Boada M, Cabañas M, Sanchez M, Arguis P, Lomeña F, Ramirez J, Molins L.

Eur J Cardiothorac Surg. 2012 Jul;42(1):93-100; discussion 100. doi: 10.1093/ejcts/ezr272. Epub 2012 Jan 20.

PMID:
22290911
15.

Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.

Rangaswamy B, Fardanesh MR, Genden EM, Park EE, Fatterpekar G, Patel Z, Kim J, Som PM, Kostakoglu L.

Laryngoscope. 2013 Nov;123(11):2664-9. doi: 10.1002/lary.24077. Epub 2013 Apr 1.

PMID:
23553147
16.

Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.

Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE.

Dis Colon Rectum. 2000 Jun;43(6):759-67; discussion 767-70.

PMID:
10859074
17.
18.

F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.

Cetina L, Serrano A, Cantú-de-León D, Pérez-Montiel D, Estrada E, Coronel J, Hernández-Lucio M, Dueñas-González A.

Rev Invest Clin. 2011 May-Jun;63(3):227-35.

PMID:
21888286
19.

A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.

Wong WL, Chevretton EB, McGurk M, Hussain K, Davis J, Beaney R, Baddeley H, Tierney P, Maisey M.

Clin Otolaryngol Allied Sci. 1997 Jun;22(3):209-14.

PMID:
9222623
20.

Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.

Sigg MB, Steinert H, Grätz K, Hugenin P, Stoeckli S, Eyrich GK.

J Oral Maxillofac Surg. 2003 Sep;61(9):1022-9.

PMID:
12966477

Supplemental Content

Support Center